Lifecore Biomedical to Participate at DCAT Week 2026
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City.
Details regarding Lifecore’s participation are as follows:
- DCAT Week 2026
Details: Lifecore team will host customers and prospective partners to discuss development and manufacturing solutions for existing and new injectable programs.
Conference Dates: March 23-26, 2026
Location: New York, NY
If you are interested in meeting with Lifecore during DCAT week, please reach out to us at: [email protected].
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 [email protected] Tim Brons (Media) 415-675-7402 [email protected] Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 [email protected]Source: Lifecore Biomedical, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BRX Coin to Launch on PancakeSwap August 9 With $500,000 Liquidity and 100% Locked LP
- RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
- Fresno State Athletics and The Wonderful Company Announce First Multi-Brand Partnership Across All Bulldog Sports
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share